Skip to content

Effectiveness of a Multidisciplinary Treatment for Patients With Chronic Low Back Pain

Effectiveness of a Multidisciplinary Treatment for Patients With Chronic Low Back Pain (PAINDOC Protocol): Randomized, Parallel-group, Two-arm, Single-blind Clinical Trial (PAINDOC Project)

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06679205
Acronym
PAINDOC
Enrollment
62
Registered
2024-11-07
Start date
2025-01-14
Completion date
2026-03-31
Last updated
2025-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Back Pain, Chronic Low-back Pain, Chronic Low-back Pain (cLBP)

Keywords

chronic low-back pain, chronic pain, pain catastrophizing, multidisciplinary treatment, therapeutic exercice, pain neuroscience education, cognitive behavioural therapy, therapeutic education

Brief summary

PAINDOC is a treatment program that includes 4 disciplines that, separately, have demonstrated their effectiveness in the treatment of chronic low back pain: education in pain neuroscience, therapeutic education (Empowered Relief®), psychotherapy based on cognitive-behavioral therapy and therapeutic exercise. The primary objective of the study is to evaluate the effectiveness of the PAINDOC multidisciplinary treatment program in reducing pain intensity and improving quality of life in persons with chronic low back pain referred to the pain unit of the Hospital Clinic of Barcelona, compared to usual care treatment. As secondary objectives, the present study aims to evaluate the effect of the PAINDOC program on: * The reduction of pain-related disability. * The reduction of pain catastrophizing. * The improvement in perceived social support. * The improvement in perceived autonomy (self-efficacy). * The reduction of analgesic, anti-inflammatory and adjuvant analgesic medication. The main questions it aims to answer are: * Is the proposed multidisciplinary treatment effective in improving pain-related outcomes? * Is the proposed multidisciplinary treatment effective in reducing analgesic medication? Participants will receive either usual care (pharmacological control) or the PAINDOC program, which consists of 7 multidisciplinary sessions within 2 months. There will be one therapeutic education session called Empowered Relief®, 2 pain neuroscience education sessions, one pain psychology session and 3 therapeutic education sessions. Besides, participants will be assessed using written questionnaires before treatment, at 3 months and at 6 months. Researchers will assess the effectiveness of the multidisciplinary treatment group comparing both groups to see if there is any difference in several pain-related outcomes.

Detailed description

Despite improving pharmacological and surgical medical treatment options, chronic low back pain is the most frequent pain disorder and a leading cause of disability. Over the past decades, clinicians have acknowledged that a broader view of disease and disability is needed in chronic conditions treatment. Therefore, biological, psychological and social factors must be addressed to improve such conditions.

Interventions

BEHAVIORALMultidisciplinary and multimodal intervention

The PAINDOC Program consists in: * Therapeutic education: The therapeutic education block consists of 2 parts: a 2-hour education session called Empowered Relief® and 2 1-hour pain neuroscience education sessions. * Psychotherapy: The psychotherapy part consists of 1 group session of 1 hour, face-to-face and with groups of up to 15 people. * Therapeutic exercise: The therapeutic exercise module consists of 3 sessions of 1 hour each, face-to-face, with small groups of between 6 and 10 patients, and given by the physiotherapist of the pain unit.

DRUGUsual Care

The pharmacological treatment will be individualised according to pain intensity, contraindications and the appearance of adverse effects.

Sponsors

Hospital Clinic of Barcelona
CollaboratorOTHER
University of Barcelona
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients over 18 years of age. * Patients with primary chronic low back pain (non-specific chronic low back pain) of axial predominance. * Experiencing pain at least 50% of the time over the last 6 months. * Average weekly pain intensity equal or greater than 4 out of 10 on a verbal numerical scale. * Be agreeable to receiving active, non-pharmacological and non-surgical treatment.

Exclusion criteria

* Inflammatory low back pain. * History of cancer in the last 5 years. * Unexplained and unintentional weight loss of 10 Kg or more over the preceding 12-month period. * Lack of control of bowel and bladder function (cauda equina). * Difficulty in performing the sessions due to severe physical disability. * Diagnosis of severe mental illness (schizophrenia, major depression, bipolar disorder, etc.). * Strong prescription opioid or parenteral medication addiction disorders. * Technical-logistical problems (inability to attend treatment sessions or inability to fill out assessment questionnaires). * Problems in understanding the content of the sessions (language barrier, severe hearing loss or severe cognitive impairment). * Have sought compensation or entered into litigation in the preceding 12-month period.

Design outcomes

Primary

MeasureTime frameDescription
Pain Intensity. Changes from baseline to 6 months.Baseline, 3 months, 6 monthsParticipants will be asked to rate their pain intensity on a horizontal 100-mm Visual Analogue Scale (VAS), ranging from 0 = no pain to 100 = worst imaginable pain. The VAS is a valid and reliable instrument compared with other pain rating scales, and has been well established in clinical practice and research for measuring pain levels in low back pain patients. For patients with subacute or chronic low back pain, the minimum clinically relevant change is considered to be at least 20 mm on a VAS.
Health-related quality of life. Changes from baseline to 6 months.Baseline, 3 months, 6 monthsThe spanish version of the Euro Quality of Life 5D-5L (EQ-5D-5L) was used to assess the health related quality of life (HRQL).(10) The EQ-5D-5L consists in two pages: the first one is based on a descriptive system that defines health in terms of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response categories: no problems, slight problems, moderate problems, severe problems, extreme problems.(10) A health state is composed by taking one level for each dimension, and a preference-based scoring function is used to convert the descriptive system to a summary index score (ranging from states worse than dead \<0 to full health 1).

Secondary

MeasureTime frameDescription
Perceived Social Support. Changes from baseline to 6 months.Baseline, 3 months, 6 monthsIt will be assessed using the Lubben Social Network Scale (LSNS-6), which was developed to assess the perceived social support of an adult person according to the size of his or her social network, the trust that these ties generate and the frequency of contacts that this person has with those around him or her. The LSNS-6 includes 6 questions divided into 2 domains: 3 on family and 3 on friendships. It is one of the most widely used by the international community and its application is simple and brief, which is of vital importance for its feasibility in the clinical setting. The Spanish version of the LSNS-6 has proven to be valid and reliable.
Pain-related Disability. Changes from baseline to 6 months.Baseline, 3 months, 6 monthsDisability will be assessed using the spanish version of the Oswestry Disability Index (ODI) questionnaire. The ODI is one of the most common specific measurement tools to evaluate the function and disability of lumbar spine pathologies. This questionnaire contains 10 items evaluated from 0 to 5 (higher values indicate greater disability), which correspond to 10 domains. The sum of the 10 scores is expressed as a percentage (ODI score), with ranges from 0% (no disability) to 100% (maximum disability).
Consumption of analgesic, anti-inflammatory and coadjuvant analgesic drugsBaseline, 3 months, 6 monthsThe doses of analgesic, anti-inflammatory and coadjuvant analgesic drugs taken by each participant will be recorded, expressed in mg/day, except for opioids, where the Morphine Equivalent Dose (MED) will be used.
Self-efficacy. Changes from baseline to 6 months.Baseline, 3 months, 6 monthsSelf-efficacy will be assessed using the Spanish version of the Chronic Pain Self-Efficacy Scale (CPSES). The CPSES is a 19-item self-administered questionnaire. Each item assesses the ability that the person believes he or she has to perform a certain task or activity and is presented in the form of a question. The person must consider each question on a 10-point Likert scale, with a range of 0 to 10, where 0 is I think I am totally incapable and 10 is I think I am totally capable. The total score can range from 0 to 190 points, indicating greater self-efficacy in chronic pain the higher the score. This questionnaire is divided into 3 dimensions: self-efficacy in symptom control, self-efficacy in physical functioning, and self-efficacy in pain management.
Pain Catastrophizing. Changes from baseline to 6 months.Baseline, 3 months, 6 monthsThe Spanish version of Pain Catastrophizing Scale (PCS) was used to asses thoughts and feelings related to pain experiences.(9) The PCS is a 13 item self-administered questionnaire composed of 3 subscales: rumination, magnification and helplessness. The PCS uses a 5-point Likert scale with responses ranging from 0 = not at all to 4 = all the time. Overall scores range from 0 to 52 points, the higher the score, the higher is the pain catastrophism level.

Countries

Spain

Contacts

Primary ContactAnna Dalmau-Roig, MD
dalmaur@clinic.cat+34 639482849
Backup ContactMarc Terradas-Monllor, PhD
marc.terradas@uvic.cat+34 652948632

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026